Abstract

BackgroundAs one of the most important brain tumors, glioblastoma (GBM) has a poor prognosis, especially in adults. Immune-related genes (IRGs) and immune cell infiltration are responsible for the pathogenesis of GBM. This study aimed to identify new tumor markers to predict the prognosis of patients with GBM.MethodsThe Cancer Genome Atlas (TCGA) database and ImmPort database were used for model construction. The Wilcoxon rank-sum test was applied to identify the differentially expressed IRGs (DEIRGs) between the GBM and normal samples. Univariate Cox regression analysis and Kaplan–Meier analysis was performed to investigate the relationship between each DEIRG and overall survival. Next, multivariate Cox regression analysis was exploited to further explore the prognostic potential of DEIRGs. A risk-score model was constructed based on the above results. The area under the curve (AUC) values were calculated to assess the effect of the model prediction. Furthermore, the Chinese Glioma Genome Atlas (CGGA) dataset was used for model validation. STRING database and functional enrichment analysis were used for exploring the gene interactions and the underlying functions and pathways. The CIBERSORT algorithm was used for correlation analysis of the marker genes and the tumor-infiltrating immune cells.ResultsThere were 198 DEIRGs in GBM, including 153 upregulated genes and 45 downregulated genes. Seven marker genes (LYNX1, PRELID1P4, MMP9, TCF12, RGS14, RUNX1, and CCR2) were filtered out by sequential screening for DEIRGs. The regression coefficients (0.0410, 1.335, 0.005, −0.021, 0.123, 0.142, and −0.329) and expression data of the marker genes were used to construct the model. The AUC values for 1, 2, and 3 years were 0.744, 0.737, and 0.749 in the TCGA–GBM cohort and 0.612, 0.602, and 0.594 in the CGGA-GBM cohort, respectively, which indicated a high predictive power. The results of enrichment analysis revealed that these genes were enriched in the activation of T cell and cytokine receptor interaction pathways. The interaction network map demonstrated a close relationship between the marker genes MMP9 and CCR2. Infiltration analysis of the immune cells showed that dendritic cells (DCs) could identify GBM, while LYNX1, RUNX1, and CCR2 were significantly positively correlated with DCs expression.ConclusionThis study analyzed the expression of IRGs in GBM and identified seven marker genes for the construction of an immune-related risk score model. These marker genes were found to be associated with DCs and were enriched in similar immune response pathways. These findings are likely to provide new insights for the immunotherapy of patients with GBM.

Highlights

  • Glioblastoma (GBM) is characterized by high mortality and accounts for 48.6% of primary malignant brain tumors [1]

  • Studies related to mutations of isocitrate dehydrogenase and platelet-derived growth factor receptor [3], as well as promoter methylation of methylguanine methyltransferase show that considerable progress has been made in the genetic research of GBM biomarkers [4–6]

  • The heat map revealed that 153 genes were upregulated and 45 genes were downregulated in the tumor samples (Supplementary Table 2)

Read more

Summary

Introduction

Glioblastoma (GBM) is characterized by high mortality and accounts for 48.6% of primary malignant brain tumors [1]. Survival prediction is important and urgent for the treatment of patients with GBM. Many new molecular markers and molecular characterization systems of GBM have emerged, which provide guidance for understanding the mechanism of progression and promote diagnosis and treatment [2]. Studies related to mutations of isocitrate dehydrogenase and platelet-derived growth factor receptor [3], as well as promoter methylation of methylguanine methyltransferase show that considerable progress has been made in the genetic research of GBM biomarkers [4–6]. As one of the most important brain tumors, glioblastoma (GBM) has a poor prognosis, especially in adults. This study aimed to identify new tumor markers to predict the prognosis of patients with GBM

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call